FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123192786> ?p ?o ?g. }

• W2123192786 endingPage "2169" @default.
• W2123192786 startingPage "2169" @default.
• W2123192786 abstract "Warfarin, which requires coagulation monitoring, is associated with relatively high rates of thromboembolism despite providing adequate prophylaxis. This study compared an oral direct thrombin inhibitor, ximelagatran, with warfarin in order to evaluate the safety and efficacy of the medication for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.Following surgery, patients were randomly assigned to fixed-dose oral ximelagatran (36 mg twice daily) or warfarin (target international normalized ratio, 2.5), both administered for seven to twelve days in a double-blind, double-dummy design. Warfarin was initiated on the evening of the day of surgery, and ximelagatran, on the morning after surgery. The primary efficacy end point was the incidence of asymptomatic deep-vein thrombosis determined by bilateral venography, objectively confirmed symptomatic deep-vein thrombosis or pulmonary embolism, and death from all causes during treatment.Adequate venograms or confirmed symptomatic events (efficacy population) were obtained for 1949 patients. Venous thromboembolism and death from all causes occurred in 22.5% (221) of 982 ximelagatran-treated patients and in 31.9% (308) of 967 warfarin-treated patients (p < 0.001). Proximal deep-vein thrombosis and pulmonary embolism were observed in 3.1% (thirty) and 0.2%, respectively, of the patients in the ximelagatran group and in 3.4% (thirty-three) and 0.4%, respectively, of the patients in the warfarin group. The six deaths from all causes included 0.3% (four) of the ximelagatran-treated patients and 0.2% (two) of the warfarin-treated patients. Major bleeding was noted in 1% (twelve) of the ximelagatran-treated patients and in 0.4% (five) of the warfarin-treated patients (p = 0.09).Oral ximelagatran (36 mg twice daily), administered without coagulation monitoring or dose adjustment and started the day after total knee arthroplasty, demonstrates superior efficacy compared with warfarin prophylaxis, with no wound complications and no significant difference with respect to bleeding events, although the rate of major bleeding events was greater with ximelagatran than with warfarin.Therapeutic Level I." @default.
• W2123192786 created "2016-06-24" @default.
• W2123192786 creator A5000127045 @default.
• W2123192786 creator A5008786748 @default.
• W2123192786 creator A5013909915 @default.
• W2123192786 creator A5031668219 @default.
• W2123192786 creator A5055052720 @default.
• W2123192786 creator A5055785288 @default.
• W2123192786 creator A5064404418 @default.
• W2123192786 creator A5064517373 @default.
• W2123192786 date "2005-10-01" @default.
• W2123192786 modified "2023-10-16" @default.
• W2123192786 title "Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty" @default.
• W2123192786 cites W1444942424 @default.
• W2123192786 cites W1489188437 @default.
• W2123192786 cites W1570220621 @default.
• W2123192786 cites W1860102466 @default.
• W2123192786 cites W1964159013 @default.
• W2123192786 cites W1979437648 @default.
• W2123192786 cites W1981993540 @default.
• W2123192786 cites W2010599049 @default.
• W2123192786 cites W2019391438 @default.
• W2123192786 cites W2022713742 @default.
• W2123192786 cites W2038537842 @default.
• W2123192786 cites W2042356029 @default.
• W2123192786 cites W2048313858 @default.
• W2123192786 cites W2054169479 @default.
• W2123192786 cites W2054740753 @default.
• W2123192786 cites W2071155706 @default.
• W2123192786 cites W2072115658 @default.
• W2123192786 cites W2085373120 @default.
• W2123192786 cites W2097827758 @default.
• W2123192786 cites W2137279768 @default.
• W2123192786 cites W2144607086 @default.
• W2123192786 cites W2167816835 @default.
• W2123192786 cites W2220791434 @default.
• W2123192786 cites W2307748339 @default.
• W2123192786 cites W2326914415 @default.
• W2123192786 cites W2424887566 @default.
• W2123192786 cites W2611712684 @default.
• W2123192786 doi "https://doi.org/10.2106/jbjs.d.02184" @default.
• W2123192786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16203879" @default.
• W2123192786 hasPublicationYear "2005" @default.
• W2123192786 type Work @default.
• W2123192786 sameAs 2123192786 @default.
• W2123192786 citedByCount "46" @default.
• W2123192786 countsByYear W21231927862012 @default.
• W2123192786 countsByYear W21231927862013 @default.
• W2123192786 countsByYear W21231927862014 @default.
• W2123192786 countsByYear W21231927862015 @default.
• W2123192786 countsByYear W21231927862016 @default.
• W2123192786 countsByYear W21231927862017 @default.
• W2123192786 countsByYear W21231927862018 @default.
• W2123192786 crossrefType "journal-article" @default.
• W2123192786 hasAuthorship W2123192786A5000127045 @default.
• W2123192786 hasAuthorship W2123192786A5008786748 @default.
• W2123192786 hasAuthorship W2123192786A5013909915 @default.
• W2123192786 hasAuthorship W2123192786A5031668219 @default.
• W2123192786 hasAuthorship W2123192786A5055052720 @default.
• W2123192786 hasAuthorship W2123192786A5055785288 @default.
• W2123192786 hasAuthorship W2123192786A5064404418 @default.
• W2123192786 hasAuthorship W2123192786A5064517373 @default.
• W2123192786 hasConcept C126322002 @default.
• W2123192786 hasConcept C141071460 @default.
• W2123192786 hasConcept C2776265017 @default.
• W2123192786 hasConcept C2776301958 @default.
• W2123192786 hasConcept C2776710957 @default.
• W2123192786 hasConcept C2778810321 @default.
• W2123192786 hasConcept C2778959117 @default.
• W2123192786 hasConcept C2779161974 @default.
• W2123192786 hasConcept C2779630707 @default.
• W2123192786 hasConcept C2780011451 @default.
• W2123192786 hasConcept C2780868729 @default.
• W2123192786 hasConcept C2908647359 @default.
• W2123192786 hasConcept C42219234 @default.
• W2123192786 hasConcept C71924100 @default.
• W2123192786 hasConcept C99454951 @default.
• W2123192786 hasConceptScore W2123192786C126322002 @default.
• W2123192786 hasConceptScore W2123192786C141071460 @default.
• W2123192786 hasConceptScore W2123192786C2776265017 @default.
• W2123192786 hasConceptScore W2123192786C2776301958 @default.
• W2123192786 hasConceptScore W2123192786C2776710957 @default.
• W2123192786 hasConceptScore W2123192786C2778810321 @default.
• W2123192786 hasConceptScore W2123192786C2778959117 @default.
• W2123192786 hasConceptScore W2123192786C2779161974 @default.
• W2123192786 hasConceptScore W2123192786C2779630707 @default.
• W2123192786 hasConceptScore W2123192786C2780011451 @default.
• W2123192786 hasConceptScore W2123192786C2780868729 @default.
• W2123192786 hasConceptScore W2123192786C2908647359 @default.
• W2123192786 hasConceptScore W2123192786C42219234 @default.
• W2123192786 hasConceptScore W2123192786C71924100 @default.
• W2123192786 hasConceptScore W2123192786C99454951 @default.
• W2123192786 hasIssue "10" @default.
• W2123192786 hasLocation W21231927861 @default.
• W2123192786 hasLocation W21231927862 @default.
• W2123192786 hasOpenAccess W2123192786 @default.
• W2123192786 hasPrimaryLocation W21231927861 @default.
• W2123192786 hasRelatedWork W1980752621 @default.

• next